@

The first step in the journey from imprecise drug therapy to precision medicine - REPO4EU’s Euro / Global Platform for Drug Repurposing

Neckargemünd, 9th August, 2022

 

The biotechnology company Sciomics GmbH, located in Neckargemünd, Germany, today announced its participation in an ambitious joint initiative selected and granted almost €23M by the European Commission as part of the Horizon Europe Programme.

REPO4EU’s ultimate goal is to build and grow an industry-level European online platform for validated precision drug repurposing with a global reach. This platform will operate as the go-to data hub for key information, training resources, matchmaking and cooperation in drug repurposing.

The platform will provide extensive expertise throughout the whole value chain in drug repurposing: from freedom-to-operate analysis to intellectual property protection and business development, health technology assessment, ethics and data governance considerations.  

During the next 7 years, 28 partners from 10 countries (The Netherlands, Germany, Austria, Spain, Sweden, Romania, Belgium, Portugal, Switzerland and the United States) will join forces to make REPO4EU a reality and create a unique platform for drug repurposing, pooling stakeholders and expertise at a global stage to create a “made in Europe”, fully-fledged infrastructure for drug repurposing. Sciomics will contribute to the initiative with its expertise and scioDiscover platform for protein biomarker discovery and verification as well as disease mechanism elucidation.

 

Drug repurposing 

But what exactly is drug repurposing? To answer this question, there is first a need to address the elephant in the room: to this day, we still rely on 19th century disease definitions – often named after specific organs, symptoms or even doctors –, when it has become painfully obvious that trying to compartmentalize the human body into small, completely isolated parts with no connection to one another is an extremely naïve endeavour.  

The truth is that our disease definitions are no longer valid – and the end of medicine as we know it is quickly approaching.  

Even though we have witnessed an exponential increase in the volume of drug discovery investments since the 80s, overall efficacy has stagnated in the pharmaceutical sector – there is currently no way of differentiating between patients who will benefit and those who will not, and unwanted side effects cannot be predicted reliably.  

The reason? There is a conceptual problem in how we define diseases and, consequently, in the way we currently approach drug development. Most underlying disease mechanisms are not understood and are thus rather treated symptomatically in an imprecise manner. 

 

Systems Medicine is organ-agnostic 

This philosophy lies at the core of what we call systems medicine: the ambition to map the full network of human diseases – the so-called diseasome – to unravel the hidden connections between mechanistically similar diseases. In the diseasome, diseases appear in clusters, indicating a common genetic origin through shared risk genes. These clusters radically change what we call a disease: now, the underlying causal molecular mechanism becomes our disease definition.

It all comes down to a very simple thought: if we can understand the underlying mechanisms that govern a specific disease, surely, we can repurpose drugs for another disease that shares some of those common elements?  

The answer is yes! Mechanism-based drug repurposing will revolutionize the way we approach drugs – it will help us find new uses for already registered drugs, increase precision and radically cut down on costs and time in the drug development process – jumping straight into clinical trials that are small, precise, innovatively designed and compliant with the highest safety and operational excellence standards.  

 

Curing diseases with high precision 

Chronic diseases are only chronic because we do not know how to cure them yet. REPO4EU’s organ-agnostic approach will push drug repurposing to its full potential by mixing Big Data, Artificial Intelligence-driven bioinformatics and Network Science with advanced cheminformatics to redefine diseases in a mechanism-based manner and repurpose drugs beyond their original target. 

REPO4EU will thereby unlock unprecedented breakthroughs in precision, efficacy and cost-effectiveness, de-risking drug repurposing and paving the way towards personalized therapies and ultimately, precision medicine.  

A resource for researchers, companies, healthcare providers, payers, and patients 

Whether you need to secure bioinformatics support for an unmet medical need, explore a registered compound or a specific mechanism; assess your freedom to operate, outline a patenting strategy or browse regulatory advice; liaise with a business partner, locate a clinical trial test site for phase I-III or craft a business plan... we have the experts and the experience to help you! 

RExPO22 - The 1st International Conference on Drug Repurposing 

REPO4EU will officially start this September, and what better way to kick things off than with a high-profile conference? We are delighted to present RExPO22, the very first instalment in our RExPO series of international conferences on drug repurposing.  

Networking has always been the prime focus of any scientific and business event and this one is both: high impact science and innovative business. Come join us September 2nd-3rd at Maastricht for two days of vibrant keynotes from world-renowned experts and busy discussion around the future of drug repurposing! 

 

Key contacts 

Coordinator: Prof. Dr. Harald HHW Schmidt, Maastricht University, This email address is being protected from spambots. You need JavaScript enabled to view it.

Sciomics: Dr. Christoph Schröder, Sciomics GmbH, This email address is being protected from spambots. You need JavaScript enabled to view it.

Communication: Diana Lopez, AUSTRALO, This email address is being protected from spambots. You need JavaScript enabled to view it.  

Project management office: Miriam Simon, concentris, This email address is being protected from spambots. You need JavaScript enabled to view it.

 

More Information:

REPO4EU initiative: https://repo4.eu
R
ExPO22 conference: https://repo4.eu/rexpo22-conference/ cropped repo4eu header 1 1

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioPhospho: protein profiling and phosphorylation status

Our scioPhospho analysis combines protein expression profiling using scioDiscover with analysis of the corresponding protein's phosphorylation status. More than 1,400 proteins are analyzed in parallel, covering key pathways in diseases such as cancer, neurological disorders and organ failure.  This combination provides a comprehensive overview of signaling events and pathway activity…
Read more
scioUbi: protein profiling and ubiquitination status

scioUbi: protein profiling and ubiquitination status

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse more than 1,400 proteins in a single assay.   Features Screen…
scioDiscover - Protein Profiling on the Expression Level

scioDiscover - Protein Profiling on the Expression Level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…
scioCD - Cell Surface Marker and Cytokine Profiling

scioCD - Cell Surface Marker and Cytokine Profiling

Characterize Your Cell Type! Cell Composition Analysis in Tissue Samples CD-Marker Expression Profiles Increased Throughput at High Sensitivity Levels High Reproducibility       Our scioCD profiling service covers 349 different…
scioCyto : Cytokine Profiling

scioCyto : Cytokine Profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or cell…

COVID-19 related activities and services

covid 19 portfolio web

News

New Article | Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia

| September 2023 | New Article: Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Sciomics supported this study by scioCyto serum analysis in a mouse cancer model.

Taylor, J., Uhl, L., Moll, I. et al. Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Nat Cancer 4, 1544–1560 (2023)
New Article | Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes

| July 2023 | New Article: Fiedler et al. developed a novel methodology for vitamin B6 diagnostics. We supported the project by the production of custom antibody microarray targeting signature human PLP-DE and testing respective samples.

New Article | Microbiota Influences Chemotherapy in Pancreatic Cancer

| February 2023 | New Article: In the study Tintelnot et al. identified a microbiota-derived metabolite that has clinical implications in the treatment of pancreatic cancer. Sciomics supported the authors by a protein profiling study of tumours derived from a mouse model upon treatment with 3-IAA and Firinox.

Tintelnot et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168-174 (2023)
New Article | Predicting a severe Covid-19 disease

| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19  disease.

Hufnagel K., Fathi A. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Communications Medicine 3,51 (2023)
New Sciomics Proteomics Research Blog has Launched!

Sciomics Protomics Research Blog

 

At Sciomics, we are dedicated to advancing healthcare through proteomics research. We are collaborating with research groups and big pharma, alongside our in-house biomarker research initiatives. To make this research more accessible to you, we are launching the new Sciomics science blog!

The first study we will feature was published this year in a journal in the Nature publishing group. It's a topic that affects us all. Any guesses? Stay tuned!

 

 

Testimonials

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD

Kyriaki Barmpa

PhD Candidate, Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine, University of Luxembourg

"By collaborating with Sciomics, we conducted a detailed analysis of the proteome of striatum organoids, uncovering significant differences that further assisted our research. Their communication was highly efficient, and the results were delivered promptly."

Product: scioPhospho